GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cynata Therapeutics Ltd (ASX:CYP) » Definitions » Total Equity

Cynata Therapeutics (ASX:CYP) Total Equity : A$12.27 Mil (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Cynata Therapeutics Total Equity?

Cynata Therapeutics's total equity for the quarter that ended in Dec. 2023 was A$12.27 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Cynata Therapeutics Total Equity Historical Data

The historical data trend for Cynata Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cynata Therapeutics Total Equity Chart

Cynata Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.97 16.79 28.37 23.96 16.73

Cynata Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.87 23.96 19.05 16.73 12.27

Cynata Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Cynata Therapeutics's Total Equity for the fiscal year that ended in Jun. 2023 is calculated as

Total Equity=Total Assets(Q: Jun. 2023 )-Total Liabilities(Q: Jun. 2023 )
=18.994-2.26
=16.73

Cynata Therapeutics's Total Equity for the quarter that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=13.452-1.182
=12.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cynata Therapeutics Total Equity Related Terms

Thank you for viewing the detailed overview of Cynata Therapeutics's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cynata Therapeutics (ASX:CYP) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cynata Therapeutics Ltd (ASX:CYP) » Definitions » Total Equity
Comparable Companies
ASX:BIT ASX:SPL ASX:EZZ ASX:ADO ASX:LTP ASX:PTX ASX:ACW ASX:PAA ASX:ATH ASX:NOX OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
51S:Germany
Address
100 Cubitt Street, Level 3, Cremorne, VIC, AUS, 3121
Website
https://www.cynata.com
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinical trials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers.

Cynata Therapeutics (ASX:CYP) Headlines

No Headlines